FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrés Cervantes

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Geographic Areas

Spain

Co-author Network

Publications

TOP 3
J A Pérez-Fidalgo; Andrés Cervantes
Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'.
Andrés Cervantes
Preoperative chemotherapy for colon cancer is getting closer.
J A Pérez Fidalgo; F Roila; C Vidall; Andrés Cervantes; L García Fabregat; A Margulies
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrés Cervantes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: J A Pérez-Fidalgo; Andrés Cervantes
Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(4):1129-30.
2012: Andrés Cervantes
Preoperative chemotherapy for colon cancer is getting closer.
The lancet oncology 2012;13(11):1073-4.
2012: J A Pérez Fidalgo; F Roila; C Vidall; Andrés Cervantes; L García Fabregat; A Margulies
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23 Suppl 7():vii167-73.
2012: Eduardo Díaz-Rubio; Carlos Fernández-Martos; Auxiliadora Gómez España; Encarnación González; José Luis Manzano; Eugenio Marcuello; Purificación Martínez de Prado; Bartomeu Massutí; Clara Montagut; Margarita Reboredo; Fernando Rivera; M José Safont; Javier Sastre; Enrique Aranda; Antonio Arrivi; Inmaculada Bando; Manuel Benavides; Andrés Cervantes
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
PloS one 2012;7(10):e47345.
2012: Eduardo Díaz-Rubio; Rosario Dueñas; Pilar Escudero; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; Adelaida Lacasta; Marta Llanos; Amelia López-Ladrón; Ferrán Losa; Eugenio Marcuello; Purificación Martínez de Prado; Bartomeu Massutí; Fernando Rivera; Maria J Safont; Javier Sastre; Josep Tabernero; Manuel Valladares; Albert Abad; Antonio Antón; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Andrés Cervantes
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
The oncologist 2012;17(1):15-25.
2011: Josep Tabernero; Ludy Van Beijsterveldt; Zhilong Yuan; Jaume Capdevila; Andrés Cervantes; Luc Dirix; Brett Hall; Roland Knoblauch; Jose A Lopez-Martin; Suso Platero; Patrick Schöffski; Sen Hong Zhuang
A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(19):6313-21.
2011: Francesco Atzori; Jordi Andreu; Robert A Beckman; Holly Brown; Emiliano Calvo; Andrés Cervantes; Jason Clark; Serena Di Cosimo; Amparo Domingo; Cristina Gamez; Jorge Guijarro; William D Hanley; James S Hardwick; Karl Hsu; Ronald B Langdon; Ludmila Prudkin; Jordi Rodon; E Rodríguez Braun; Susana Roselló; Josep Tabernero; José Baselga
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(19):6304-12.
2011: Andrés Cervantes
Growth factor receptor-related therapy for gastric cancer.
European journal of cancer (Oxford, England : 1990) 2011;47 Suppl 3():S324-5.
2011: Ana Oaknin; Jordi Ponce; Andrés Redondo; Desamparado Roda; Sílvia Catot; Andrés Cervantes; Luis Chiva; Ana de Juan; J M Del Campo; Yolanda García; Jesús García-Donas; Antonio González-Martín; Sergio Martínez; Andres Poveda
Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(6):1048-55.
2011: Matteo Frasson; Eduardo Garcia-Granero; Samuel Navarro; Desamparados Roda; Susana Roselló; Salvador Campos; Pedro Esclapez; Carmen Faus; Blas Flor-Lorente; Andrés Cervantes
Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer.
Cancer 2011;117(14):3118-25.
2011: J Alejandro Pérez Fidalgo; Ana Hernández Machancoses; Víctor Martín González; Andrés Cervantes
Treatment of cervical cancer: the importance of a multidisciplinary team approach.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(7):431-3.
2011: Fernando Rivera; Maica Galán; Josep Tabernero; Andrés Cervantes; Maria Eugenia Vega-Villegas; Javier Gallego; Berta Laquente; Edith Rodríguez; Alfredo Carrato; Pilar Escudero; Bartomeu Massutí; Vicente Alonso-Orduña; Adelaida Cardenal; Alberto Sáenz; Jordi Giralt; Ana Lucia Yuste; Antonio Antón; Enrique Aranda
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Cancer chemotherapy and pharmacology 2011;67(1):75-82.
2009: José Alejandro Pérez Fidalgo; Desamparados Roda; Susana Roselló; E Rodríguez Braun; Andrés Cervantes
Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2009;11(12):787-98.
2009: Fernando Rivera; Maica Galán; Josep Tabernero; Andrés Cervantes; M Eugenia Vega Villegas; Javier Gallego; Berta Laquente; Edith Rodríguez; Alfredo Carrato; Pilar Escudero; Bartomeu Massutí; Vicente Alonso-Orduña; Adelaida Cardenal; Alberto Sáenz; Jordi Giralt; Ana L Yuste; Antonio Antón; Enrique Aranda
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
International journal of radiation oncology, biology, physics 2009;75(5):1430-6.
2009: Andrés Cervantes
ECCO 15: 34th ESMO Multidisciplinary Congress in Berlin: a step forward to a high-quality global oncology forum.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2009;11(10):629-30.
2009: Luis Sabater; Julio Calvete; Luis Aparisi; Raul Cánovas; Elena Muñoz; Ramón Añón; Susana Roselló; Edith Rodríguez; Bruno Camps; Raquel Alfonso; Carlos Sala; Juan Sastre; Andrés Cervantes; Salvador Lledó
[Pancreatic and periampullary tumors: morbidity, mortality, functional results and long-term survival].
Cirugía española 2009;86(3):159-66.
2009: Eduardo García-Granero; Omar Faiz; Elena Muñoz; Blas Flor; Samuel Navarro; Carmen Faus; Stephannie Anne García-Botello; Salvador Lledó; Andrés Cervantes
Macroscopic assessment of mesorectal excision in rectal cancer: a useful tool for improving quality control in a multidisciplinary team.
Cancer 2009;115(15):3400-11.
2009: Andrés Cervantes
Continuing medical education (CME) or continuing professional development (CPD): a need, a challenge, but also a must.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2009;11(4):189-90.
2008: Andrés Cervantes; S Roselló; E Rodríguez Braun; S Navarro; S Campos; A Hernández; Eduardo García-Granero
Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 7():vii266-72.
2008: Andrés Cervantes; S Roselló; D Roda; E Rodríguez Braun
The treatment of advanced gastric cancer: current strategies and future perspectives.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 5():v103-7.
2008: Josep Tabernero; Per Pfeiffer; Andrés Cervantes
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
The oncologist 2008;13(2):113-9.
2007: Josep Tabernero; Eric Van Cutsem; Eduardo Díaz-Rubio; Andrés Cervantes; Yves Humblet; Thierry André; Jean-Luc Van Laethem; Patrick Soulié; Esther Casado; Chris Verslype; Javier Sastre Valera; Giampaolo Tortora; Fortunato Ciardiello; Oliver Kisker; Aimery de Gramont
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5225-32.
2007: Aimery de Gramont; Marc Buyse; Jose Cortinas Abrahantes; Tomasz Burzykowski; Emmanuel Quinaux; Andrés Cervantes; Arie Figer; Gérard Lledo; Michel Flesch; Laurent Mineur; Elisabeth Carola; Pierre-Luc Etienne; Fernando Rivera; Isabel Chirivella; Nathalie Perez-Staub; Christophe Louvet; Thierry André; Isabelle Tabah-Fisch; Christophe Tournigand
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3224-9.
2007: José Ignacio Martínez-Ferrandis; Miguel A Soriano; Alicia Martínez-Romero; Guadalupe Herrera; Andrés Cervantes; Jose-Enrique O'Connor; Erwin Knecht; M-Eugenia Armengod
Efficient selection of silenced primary cells by flow cytometry.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2007;71(8):599-604.
2007: Andrés Cervantes; E Rodríguez Braun; S Navarro; A Hernández; S Campos; Eduardo García-Granero
Integrative decisions in rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 9():ix127-31.
2007: Andrés Cervantes; E Rodríguez Braun; A Pérez Fidalgo; I Chirivella González
Molecular biology of gastric cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(4):208-15.
2007: José I Martinez-Ferrandis; Raquel Rodríguez-López; Roger L Milne; Emilio González; Elvira Cebolla; Isabel Chirivella; Pilar Zamora; José Ignacio Arias; Santiago Palacios; Andrés Cervantes; Orland Díez; Javier Benitez; M-Eugenia Armengod
Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women.
Cancer biomarkers : section A of Disease markers 2007;3(2):89-93.
2006: Andrés Cervantes; Isabel Chirivella; E Rodriguez-Braun; S Campos; S Navarro; Eduardo García-Granero
A multimodality approach to localized rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x129-34.
2006: Matilde Navarro; Emma Dotor; Fernando Rivera; Pedro Sánchez-Rovira; Maria Eugenia Vega-Villegas; Andrés Cervantes; José Luis García; Manel Gallén; Enrique Aranda
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
International journal of radiation oncology, biology, physics 2006;66(1):201-5.
2006: Enrique Aranda; Albert Abad; Alfredo Carrato; Andrés Cervantes; Josep Tabernero; Eduardo Díaz-Rubio
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2006;8(2):98-102.
2006: Christophe Tournigand; Andrés Cervantes; Arie Figer; Gérard Lledo; Michel Flesch; Marc Buyse; Laurent Mineur; Elisabeth Carola; Pierre-Luc Etienne; Fernando Rivera; Isabel Chirivella; Nathalie Perez-Staub; Christophe Louvet; Thierry André; Isabelle Tabah-Fisch; Aimery de Gramont
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):394-400.
2005: Ricardo Hitt; Antonio López-Pousa; Javier Martínez-Trufero; Vicente Escrig; Joan Carles; Alfredo Rizo; Dolores Isla; M Eugenia Vega; Juan L Martí; Francisco Lobo; Pedro Pastor; Vicente Valentí; Joaquín Belón; Miguel A Sánchez; Carlos Chaib; Cinta Pallarés; Antonio Antón; Andrés Cervantes; Luis Paz-Ares; Hernán Cortés-Funes
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8636-45.
2005: Joan Maurel; Andrés Cervantes; Carlos Conill; Ramón Salazar; Marta Martin-Richard; Manuel Pera; Hermini Manzano; Isabel Chirivella; Rosa Gallego; Xavier Marfa
Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
International journal of radiation oncology, biology, physics 2005;62(1):91-6.
2005: Antonio González-Martín; E Calvo; Isabel Bover; M J Rubio; Angels Arcusa; Antonio Casado; Belén Ojeda; Carmen Balañá; E Martínez; A Herrero; B Pardo; Encarna Adrover; J Rifá; M J Godes; Alfredo Moyano; Andrés Cervantes
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(5):749-55.
2005: Albert Abad; Alfredo Carrato; Matilde Navarro; Javier Sastre; Andrés Cervantes; Antonio Antón; Mercedes Martinez-Villacampa; Eugenio Marcuello; Bartomeu Massutí; Enrique Aranda; José Luis Manzano; José Luis Guallar; Eduardo Diaz-Rubio
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Clinical colorectal cancer 2005;4(6):384-9.
2004: Enrique Aranda; Alfredo Carrato; Andrés Cervantes; Javier Sastre; M A Gómez; Albert Abad; Bartomeu Masutti; F Ribera; Eugenio Marcuello; L Pronk; Miquel Balcells; Eduardo Díaz-Rubio
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(4):559-67.
2004: Andrés Cervantes; Isabel Chirivella
Oncological emergencies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv299-306.
2003: José Ignacio Martínez-Ferrandis; Ana Vega; Isabel Chirivella; pablo marin-garcia; Amelia Insa; Ana Lluch; Angel Carracedo; Felipe J Chaves; J García-Conde; Andrés Cervantes; M-Eugenia Armengod
Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.
Human mutation 2003;22(5):417-8.
2003: Orland Díez; Ana Osorio; Mercedes Durán; José Ignacio Martinez-Ferrandis; Miguel de la Hoya; Raquel Salazar; Ana Vega; Berta Campos; Raquel Rodríguez-López; Eladio Velasco; Javier Chaves; Eduardo Díaz-Rubio; Juan Jesús Cruz; María Torres; Eva Esteban; Andrés Cervantes; Carmen Alonso; Juan Manuel San Román; Rogelio González-Sarmiento; Cristina Miner; Angel Carracedo; María Eugenia Armengod; Trinidad Caldés; Javier Benítez; Montserrat Baiget
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Human mutation 2003;22(4):301-12.
2000: Aimery de Gramont; Arie Figer; Matthew T Seymour; M Homerin; A Hmissi; Jim Cassidy; C Boni; H Cortes-Funes; Andrés Cervantes; G Freyer; D Papamichael; N Le Bail; Christophe Louvet; D Hendler; F de Braud; C Wilson; François Morvan; A Bonetti
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(16):2938-47.
1999: E Díáz-Rubio; Javier Sastre; Albert Abad; Matilde Navarro; Enrique Aranda; Alfredo Carrato; Manel Gallén; Eugenio Marcuello; J Rifá; T Massuti; Andrés Cervantes; Antonio Antón; Carlos Fernández-Martos
UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):35-40.
1998: Albert Abad; Bartomeu Massuti; E Blanco; Alfredo Carrato; Joan Maurel; Andrés Cervantes; Enrique Aranda; Antonio Antón; José María Vicent; J Dorta; M L Garcia de Paredes; A Ariza
Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial.
American journal of clinical oncology 1998;21(2):151-4.
1996: Enrique Aranda; Andrés Cervantes; Alfredo Carrato; C Fernández-Martos; A Antón-Torres; T Massutí; Isidoro Barneto; Javier García Conde; J M Barón; Eduardo Díaz-Rubio
Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(6):581-5.
1996: Bruno Audhuy; P Cappelaere; M Martin; Andrés Cervantes; Michel Fabbro; A Rivière; David Khayat; H Bleiberg; M Faraldi; N Claverie; Enrique Aranda; Gérard Auclerc; B Audhuy; A Benhammouda; H Bleiberg; L Cals; P Cappelaere; A Cattan; A Cervantes; Bernard Chevallier; Thierry Conroy; Didier Cupissol; J De Grève; Eduardo Diaz-Rubio; J F Seitz
A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
European journal of cancer (Oxford, England : 1990) 1996;32A(5):807-13.
1996: Enrique Aranda; Andrés Cervantes; Alfredo Carrato; A Antón-Torres; T Massutí; C Fernández-Martos; Eduardo Díaz-Rubio
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
The Journal of infusional chemotherapy 1996;6(3):118-22.
1995: Enrique Aranda; Andrés Cervantes; J Dorta; E Blanco; C Fernández-Martos; J J Cruz-Hernandez; Alfredo Carrato; R Gonzalez-Mancha; Javier García Conde; Eduardo Díaz-Rubio
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Cancer 1995;76(4):559-63.
1994: Javier García Conde; A Lluch; M Martin; Antonio Casado; H Gervasio; C De Oliveira; J L De Pablo; J Gorostiaga; G C Girón; Andrés Cervantes
Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(9):854-7.
1994: Ana Lluch; P Azagra; Andrés Cervantes; M Muñoz; Vicente Alberola; P Santabarbara; Javier García Conde
Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma.
Oncology 1994;51(4):352-5.
1993: Andrés Cervantes; A Villar-Grimalt; Albert Abad; A Antón-Torres; J Belón; J Dorta; A Tres; Carlos Camps; E Fonseca; Bartomeu Massutí
5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):753-7.
1992: Eduardo Díaz-Rubio; J Jimeno; Enrique Aranda; Bartomeu Massuti; Carlos Camps; Andrés Cervantes; J Dorta; J J Cruz Hernández; S Dominguez; A Anton
Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(10):861-3.
1987: A Lluch; A Artero; Andrés Cervantes; J M Vicent; G Codina; G Barrajón; M T Rabena; Vicente Alberola; Javier García Conde
[Estrogen and progesterone receptors in cancer of the breast].
Medicina clínica 1987;89(11):456-9.
1987: A Lluch; A Pascual; Andrés Cervantes; Antonio Antón; A Martínez Agulló; J Aviñó; Vicente Alberola; Javier García Conde
[Treatment of locally advanced cancer of the breast].
Medicina clínica 1987;89(1):7-10.